Festal - dragee 100 pcs., three-component enzyme agent

White, glossy, round dragees with a faint vanilla smell.

pharmachologic effect

The drug compensates for the lack of exocrine pancreatic function due to pancreatin, and the biliary function of the liver due to the bile component.

Festal has proteolytic, amylolytic and lipolytic effects.

Enzymes included in pancreatin: amylase, lipase and protease facilitate the digestion of carbohydrates, fats and proteins, which contributes to their more complete absorption in the small intestine.

And in this respect, Festal practically does not differ from other enzyme preparations.

The presence of bile acids in Festal gives the drug additional opportunities for correcting biliary insufficiency, which often accompanies chronic pancreatitis.

The bile extract acts as a choleretic, facilitates the absorption of fats and fat-soluble vitamins A, E and K, promotes the release of lipase by the pancreas.

Name ENG

FESTAL

Clinical and pharmacological group

Enzyme preparation

ATX code

A09AA02

Dosage

Pancreatin - 192 mg equivalent (amylase - 4500 FIP U, lipase - 6000 FIP U, protease -

300 FIP UNITS)

Hemicellulase - 50 mg

Bile components - 25 mg

Structure

Core composition

Active substances:

Pancreatin - 192 mg equivalent (amylase - 4500 FIP U, lipase - 6000 FIP U, protease -

300 FIP UNITS)

Hemicellulase - 50 mg

Bile components - 25 mg

Excipients: sodium chloride

Indications

Insufficiency of exocrine pancreatic function in chronic

pancreatitis in combination with biliary insufficiency due to various

pathological conditions, clinically manifested by impaired digestion of food,

flatulence, a tendency to constipation, as part of a combination therapy for:

- diffuse liver diseases - alcoholic and toxic liver damage, cirrhosis

liver

- large losses of bile acids (in patients after cholecystectomy)

- violation of the circulation of bile acids, observed with dyskinesias

biliary tract, dysbiosis, malabsorption

- violation of neurohumoral regulation of the processes of bile formation and bile secretion

with chronic diseases of the gastrointestinal tract - chronic gastritis,

chronic duodenitis, chronic cholecystitis

INN / Active ingredient

Pancreatin

Hemicellulase

Bile components

Contraindications

Hypersensitivity to the components of the drug, acute pancreatitis,

exacerbation of chronic pancreatitis, liver failure, hepatic coma

or precoma, hepatitis, hyperbilirubinemia, obstructive jaundice, gallstone

disease, empyema of the gallbladder, intestinal obstruction, tendency to diarrhea,

children's age up to 3 years, pregnancy and the period of breastfeeding.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

Specifications

Category

Preparations for the gastrointestinal tract

Scope of the medicinal product

Gastrointestinal tract

Release form

Dragee

Manufacturer country

India

Package quantity, pcs

one hundred

Scope of application

Gastroenterology

Minimum age from

3 years old

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Sanofi

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Cell-free contoured packaging (strip)

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Digestive Enzyme Remedy

Anatomical and therapeutic characteristics

A09AA02 Polyenzyme preparations (lipase + protease, etc.)

Dosage form

Dragee

Dosage (volume) of the substance in the preparation

200 mg

Expiration date in days

1095

Package weight, g

fifty

Mode of application

:

Inside.

The drug is taken orally, without chewing, during or immediately after a meal, with a drink.

a little liquid.

Assign 1-2 pills 3 times a day.

Higher doses are prescribed only by a doctor.

The dosage and dosage regimen in children is determined by the doctor.

The duration of treatment can vary from several days (in case of violation

the digestive process due to errors in the diet) up to several months or years (with

the need for constant substitution therapy).

Before X-ray or ultrasound examination - 2 tablets 2-3 times a day

2-3 days before the study.